CKM and cardiac hypertrophy: This is further supported by a recent study that showed correction of cardiac hypertrophy in the Mck conditional knockout mouse model by AAV-mediated FXN gene therapy, where frataxin was overexpressed tenfold over the level of endogenous frataxin expression without deleterious side effects in the treated mice.20